# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 EPAS ID: PAT6030489

Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
OLGA GOLONZHKA	01/08/2020
MATTHEW B. JARPE	01/08/2020

#### **RECEIVING PARTY DATA**

Name:	ACETYLON PHARMACEUTICALS, INC.	
Street Address:	70 FARGO STREET	
City:	BOSTON	
State/Country:	MASSACHUSETTS	
Postal Code: 02210		

## **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	16026651

### **CORRESPONDENCE DATA**

**Fax Number:** (857)300-4001

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 857-300-4003

**Email:** bostonpatent@lathropgage.com,dvincent@lathropgage.com,dpstein@lathropgage.com

Correspondent Name: BRIAN C. TRINQUE
Address Line 1: LATHROP GPM LLP
Address Line 2: 28 STATE STREET

Address Line 4: BOSTON, MASSACHUSETTS 02109

ATTORNEY DOCKET NUMBER:	602648: RGT-037CON	
NAME OF SUBMITTER: BRIAN C. TRINQUE, PH.D., ESQ.		
SIGNATURE: /BRIAN C. TRINQUE/		
DATE SIGNED:	03/25/2020	

## **Total Attachments: 4**

source=602648-ACT-037CON-EXECUTED-INVENTOR-ASSIGNMENT-3-25-2020#page1.tif source=602648-ACT-037CON-EXECUTED-INVENTOR-ASSIGNMENT-3-25-2020#page2.tif source=602648-ACT-037CON-EXECUTED-INVENTOR-ASSIGNMENT-3-25-2020#page3.tif source=602648-ACT-037CON-EXECUTED-INVENTOR-ASSIGNMENT-3-25-2020#page4.tif

PATENT 505983781 REEL: 052221 FRAME: 0880

U.S. Application No.: 15/335,971 Attorney Docket No.:585377: ACT-037

Filed: October 27, 2016

### **ASSIGNMENT**

WHEREAS, we, Olga Golonzhka of Watertown, Massachusetts, a citizen of the United States, and Matthew B. Jarpe of Quincy, Massachusetts, a citizen of the United States, have invented a certain new and useful invention, described in the following patent application:

HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY U.S. Patent Application No. 15/335,971, filed October 27, 2016

for which we are about to make or have made application for Patent of the United States; and

WHEREAS, ACETYLON PHARMACEUTICALS, INC. (hereinafter referred to as Assignee) a corporation having its principal place of business at 70 Fargo Street, Suite 205, Boston, Massachusetts 02210-2138, is desirous of acquiring all rights, title and interests in and to said invention, said applications, and in and to any and all patents which may be granted for or upon said invention and applications in the United States of America and anywhere in the world.

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, we, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, and this patent application, and all divisions, and continuations thereof, and all Patents of the United States which may be granted thereon, and all reissues thereof, and all rights to claim priority in any foreign country on the basis of the above patent application (if any), as well as all rights to claim priority on the basis of this application in any foreign country, and all applications for patent which may hereafter be filed for this invention in any foreign country, and all extensions, renewals, and reissues thereof, as well as supplementary protection certificates; and we hereby authorize and request the

1 of 3

U.S. Application No.: 15/335,971 Attorney Docket No.:585377: ACT-037

Filed: October 27, 2016

Director of the United States Patent and Trademark Office and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all patents for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE HEREBY covenant that we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE HEREBY further covenant and agree that we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns;

AND, WE HEREBY authorize and request, if necessary, that the attorneys having Power of Attorney in this application, insert above the filing date and application number of said application when known.

ALL of the above shall be held and enjoyed by said ACETYLON PHARMACEUTICALS, INC. for its own use and benefit, and for its successors, legal representatives and assigns, to the full end of the term for which said patent may be granted, and we do hereby authorize and request the Commissioner of Patents and Trademarks to issue the patent in accordance with this Assignment.

This assignment to have effect as of the filing date of October 27, 2016.

U.S. Application No.: 15/335,971 Attorney Docket No.:585377: ACT-037

Filed: October 27, 2016

This assignment to have effect as of the filing date of October 27, 2016.

'S Jai	wary dodo	O alleffy
Date:	0	Olga Golonzhka
Signed in m above referr		vledged to be an assignment of the application herein
WITNESS		
<b>ブ</b> nk Name	nk Choi	
Signature	3 (1986) and the little	
Date	nuary 2020	
Date:	······································	Matthew B. Jarpe
Signed in m above referr		vledged to be an assignment of the application herein
WITNESS		
Name		
Signature		······································
Date		

3 of 3

U.S. Application No.: 15/335,971 Attorney Docket No.:585377; ACT-037

Filed: October 27, 2016

Date:	Olga Golonzhka	
Signed in my presence and acknowledged t above referred to:	o be an assignment of the application herein	
WITNESS		
Name		
Signature		
Date		
08 SM 2020	Memo	
Date:	Matthew B. Jarpe	
Signed in my presence and acknowledged to be an assignment of the application herein above referred to:		
WITNESS		
Anna Borry		
Name Of Control of Con		
Signature		
Jan 8, 2020		
Date		

3 of 3

**RECORDED: 03/25/2020**